Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Esperion has been granted a five-year patent extension for Bempedoic Acid, a key drug in its portfolio. This extension enhances the drug's commercial lifespan and potentially its profitability.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:16 pm

HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) with a maintained price target of $16.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 1:33 pm

Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 5:57 pm

Esperion Therapeutics shares surged following the announcement of their Q1 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 2:27 pm

Esperion Therapeutics (NASDAQ:ESPR) reported a significant increase in first-quarter revenues, reaching $137.74 million, a 467% increase year-over-year, and surpassing consensus estimates of $84.51 million. The company also reported an EPS of $0.34, beating the consensus of $0.05 and marking a turnaround from a loss of $(0.79) a year ago. The revenue boost was attributed to U.S. net product revenue growth of 46% Y/Y and collaboration revenue of $113.0 million, driven by increased tablet sales and a settlement-related milestone payment. The FDA approved new label expansions for NEXLETOL and NEXLIZET tablets, and the company has initiated commercial initiatives to increase patient awareness. Esperion also began the technology transfer process for tablet manufacturing to Daiichi Sankyo Europe and authorized commercialization of a new triple formulation product. The company expects FY 2024 operating expenses to be between $225 million and $245 million. ESPR shares rose 5.20% to $2.23.

Portfolio Pulse from Vandana Singh

May 07, 2024 | 2:20 pm

Esperion Therapeutics projects its FY24 operating expenses to be between $225M-$245M, which includes $20M in non-cash expenses due to stock compensation.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 2:19 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. FibroGen, Envoy Medical, iSpecimen, NovaBay Pharmaceuticals, GT Biopharma, and Esperion Therapeutics were among the gainers, with notable increases in their stock prices following their Q1 earnings reports. Conversely, Helius Medical Tech, Cellectis, Eledon Pharma, Fresenius Medical Care, Madrigal Pharmaceuticals, and Context Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 12:06 pm

Esperion Therapeutics' stock is trading higher following the announcement of their Q1 financial results, which exceeded expectations, and the company's issuance of revenue guidance for FY24.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:24 am

Esperion Therapeutics projects its FY24 revenues to be between $225M-$245M, which includes $20M in non-cash expenses related to stock compensation.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 10:04 am

Esperion Therapeutics (NASDAQ:ESPR) reported Q1 earnings of $0.34 per share, surpassing the $0.05 estimate, a 143.04% increase from last year's losses. Sales reached $137.74M, beating the $84.51M estimate, marking a 466.14% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 10:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.